For research use only. Not for therapeutic Use.
PK68(Cat No.:I018664) is a selective and potent type II inhibitor of receptor-interacting kinase 1 (RIPK1) with an IC50 of approximately 90 nM. It inhibits RIPK1-dependent necroptosis and has the potential for use in the treatment of inflammatory disorders and cancer metastasis. PK68 ameliorates TNF-induced systemic inflammatory response syndrome with great efficacy.
Catalog Number | I018664 |
CAS Number | 2173556-69-7 |
Molecular Formula | C₂₂H₂₄N₄O₃S |
Purity | ≥95% |
Storage | Store at -20°C |
IUPAC Name | cyclohexyl N-[5-(2-acetamido-1,3-benzothiazol-6-yl)-2-methylpyridin-3-yl]carbamate |
InChI | InChI=1S/C22H24N4O3S/c1-13-19(26-22(28)29-17-6-4-3-5-7-17)10-16(12-23-13)15-8-9-18-20(11-15)30-21(25-18)24-14(2)27/h8-12,17H,3-7H2,1-2H3,(H,26,28)(H,24,25,27) |
InChIKey | DRCNWQYEKZTTEW-UHFFFAOYSA-N |
SMILES | CC1=C(C=C(C=N1)C2=CC3=C(C=C2)N=C(S3)NC(=O)C)NC(=O)OC4CCCCC4 |
Reference | [1]. Hou J, et al. Discovery of potent necroptosis inhibitors targeting RIPK1 kinase activity for the treatment of inflammatory disorder and cancer metastasis. Cell Death Dis. 2019 Jun 24;10(7):493. |